Menu
Back to User profile » Professor Josep Darbà
Papers published by Professor Josep Darbà:
Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden
Darbà J, Ascanio M, Syk J, Alving K
ClinicoEconomics and Outcomes Research 2021, 13:289-297
Published Date: 23 April 2021
Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain
Darbà J, Ramírez G, García-Rivero JL, Mayoralas S, Pascual JF, Vargas D, Bijedic A
ClinicoEconomics and Outcomes Research 2017, 9:127-137
Published Date: 10 February 2017
A budget impact analysis of Spiromax® compared with Turbuhaler® for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
Darbà J, Ramírez G, García-Rivero JL, Mayoralas-Alises S, Pascual JF, Roger A,Vargas D, Bijedic A
ClinicoEconomics and Outcomes Research 2016, 8:435-444
Published Date: 6 September 2016
Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance
Darbà J, Ramírez G, Sicras A, García-Bujalance L, Torvinen S, Sánchez-de la Rosa R
Patient Preference and Adherence 2016, 10:135-145
Published Date: 9 February 2016
The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients
Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2335-2345
Published Date: 29 October 2015
Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
Darbà J, Kaskens L
ClinicoEconomics and Outcomes Research 2015, 7:387-395
Published Date: 2 July 2015
Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
Darbà J, Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A
ClinicoEconomics and Outcomes Research 2015, 7:163-171
Published Date: 23 March 2015
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Darbà J, Kaskens L, Sorio Vilela F, Lothgren M
ClinicoEconomics and Outcomes Research 2015, 7:105-117
Published Date: 9 February 2015
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
Darbà J, Kaskens L, Sánchez-de la Rosa R
ClinicoEconomics and Outcomes Research 2014, 6:1-9
Published Date: 16 December 2013
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
Darbà J, Pérez-Álvarez N, Kaskens L, Holgado-Pérez S, Racketa J, Rejas J
ClinicoEconomics and Outcomes Research 2013, 5:327-336
Published Date: 5 July 2013